In this episode, Karim Fizazi, MD, PhD, and Alicia K. Morgans, MD, MPH, discuss the clinical implications of the latest data on androgen receptor–targeting agents in the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC). Topics include:

• Updated safety and patient preference data from the ARAMIS and ODENZA trials
• Choice of apalutamide, darolutamide, and enzalutamide
• Counseling patients on adverse events
• Managing patients with asymptomatic nonmetastatic CRPC

Presenters:

Karim Fizazi, MD, PhD
Full Professor
Cancer Medicine
Gustave Roussy
Villejuif, France  

Alicia K. Morgans, MD, MPH
Associate Professor
Division of Oncology
Department of Medicine
Northwestern University
Chicago, Illinois  

Link to full program, including downloadable slides:
https://bit.ly/36IEnNE

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.